Business Context and Reporting Period
Company: Sharps Technology, Inc. (STSS)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter ended March 31, 2026
Business Overview: The Company operates in two segments: Medical Device (sales and distribution of syringes) and Digital Commodity Treasury. In October 2025, the Company discontinued manufacturing operations and transferred its Hungarian subsidiary (Safegard Medical Kft) to a third party, classifying it as a discontinued operation. In August 2025, the Company adopted a treasury strategy focused on accumulating Solana (SOL).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $192,780 | $0 |
| Staking Revenue (Net) | $3,134,109 | $0 |
| Net Income (Loss) | $(86,239,232) | $1,928,834 |
| Loss Per Share (Basic & Diluted) | $(1.19) | $38.63 |
| Cash and Cash Equivalents | $12,320,547 | $11,894,938 |
| Digital Commodities (Fair Value) | $162,490,274 | $250,111,125 |
| Total Assets | $181,002,610 | $269,075,173 |
| Total Liabilities | $2,219,220 | $4,695,027 |
| Working Capital | $16,160,964 | $14,187,484 |
Material Changes vs. Prior Period
- Significant Net Loss: The Company reported a net loss of $86.2 million in Q1 2026, compared to a net income of $1.9 million in Q1 2025. This reversal is primarily driven by a $70.8 million unrealized loss and a $10.8 million realized loss on digital commodities (SOL).
- Digital Asset Valuation: The fair value of digital commodities decreased by approximately $87.6 million (from $250.1M to $162.5M) due to market price declines in SOL.
- Operating Expenses: Total operating expenses surged to $89.4 million from $1.4 million. This includes $2.5 million in related-party consulting fees and $2.2 million in stock-based compensation, alongside the digital commodity losses.
- Debt Repayment: The Company repaid a $3.1 million margin loan in February 2026, reducing total liabilities significantly.
- Share Repurchases: The Company repurchased 867,678 shares of common stock for approximately $1.6 million under its 2025 Repurchase Program.
Guidance, Outlook, and Risks
- Treasury Strategy: Management intends to fund operations and expansion by selling portions of its SOL holdings. Approximately 95% of SOL holdings are currently staked.
- Market Risk: The Company is highly exposed to SOL market volatility. A hypothetical 10% change in SOL fair value would impact pre-tax income by approximately $7.1 million.
- Related Party Commitments: The Company has a 20-year consulting agreement with Sol Edge Limited (related to the CIO's brother). The agreement includes a liquidated damages clause requiring payment of all future fees if terminated early by the Company.
- Subsequent Events (Post-March 31, 2026):
- Adoption of a Stockholder Rights Plan ("Poison Pill") triggered at 15% ownership.
- New employment agreements for the CEO and CIO with $600,000 annual base salaries and severance provisions.
- Lease of new office space in Hong Kong.
Investor Verification Checklist
- SOL Valuation Methodology: Verify the discount rate applied to "Locked SOL" (9% as of March 31, 2026) and the impact of unlocking schedules on future earnings.
- Related Party Fees: Review the terms of the $10M annual consulting fee paid to Sol Edge Limited and the potential liability for liquidated damages.
- Liquidity vs. Asset Concentration: Assess the risk of holding ~90% of total assets in a single volatile digital asset (SOL) versus the company's cash burn rate.
- Stockholder Rights Plan: Evaluate the implications of the newly adopted rights plan on potential M&A activity and shareholder value.
- Discontinued Operations: Confirm the final status of the Hungarian subsidiary transfer and ensure no residual liabilities remain.